New cell therapy trial targets tough blood cancers and anemia
NCT ID NCT07205315
Summary
This early-phase study is testing a new cell therapy called GT801 in adults with advanced blood cancers or autoimmune anemia that has not responded to standard treatments. The main goals are to check if the treatment is safe and to see early signs of whether it helps control the diseases. Researchers will enroll about 28 participants who have already tried at least two other drug therapies without success.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
-
Zhengzhou Yihe Hospital
RECRUITINGZhengzhou, Henan, 450018, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.